Chi Advisors LLC Inozyme Pharma, Inc. Transaction History

Chi Advisors LLC

$203 Million
Q3 2023

A detailed history of Chi Advisors LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 1,270,027 shares of INZY stock, worth $3.71 Million. This represents 2.63% of its overall portfolio holdings.

Number of Shares

1,270,027

Previous 1,195,027 6.28%

Holding current value

$3.71 Million

Previous $6.66 Million 19.86%

% of portfolio

2.63%

Previous 2.5%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$4.09 - $7.0 $306,750 - $525,000	75,000 Added 6.28%	1,270,027 $5.33 Million
Q2 2023 Aug 11, 2023	SELL	$4.93 - $6.74 $725,518 - $991,885	-147,164 Reduced 10.96%	1,195,027 $6.66 Million
Q1 2023 May 11, 2023	SELL	$1.3 - $5.73 $1.12 Million - $4.94 Million	-862,685 Reduced 39.13%	1,342,191 $7.69 Million
Q4 2022 Feb 13, 2023	BUY	$1.05 - $2.82 $219,028 - $588,249	208,599 Added 10.45%	2,204,876 $2.32 Million
Q3 2022 Nov 09, 2022	SELL	$2.57 - $5.45 $96,439 - $204,511	-37,525 Reduced 1.85%	1,996,277 $5.35 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.96 $3.65 Million - $6.8 Million	1,141,745 Added 127.99%	2,033,802 $9.7 Million
Q4 2021 Feb 11, 2022	SELL	$5.58 - $11.5 $157,395 - $324,380	-28,207 Reduced 3.07%	892,057 $6.08 Million
Q3 2021 Nov 15, 2021	SELL	$11.12 - $19.4 $77,840 - $135,800	-7,000 Reduced 0.75%	920,264 $10.7 Million
Q1 2021 May 14, 2021	SELL	$17.77 - $27.9 $1.21 Million - $1.9 Million	-68,132 Reduced 6.84%	927,264 $18.4 Million
Q4 2020 Feb 12, 2021	SELL	$19.95 - $27.55 $273,733 - $378,013	-13,721 Reduced 1.36%	995,396 $20.5 Million
Q3 2020 Nov 12, 2020	BUY	$17.54 - $30.2 $17.7 Million - $30.5 Million	1,009,117 New	1,009,117 $26.5 Million

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $117M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.

Account